Switch theme
Sign up to access all valuation multiples
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in Mainland China. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain. The company generates the majority of its revenue from the Sale of pharmaceutical products. The company also generates a small portion of its revenue from Licensing income.
2018
498
LTM Revenue $54.7M
Last FY EBITDA -$38.6M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lepu Biopharma has a last 12-month revenue (LTM) of $54.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Lepu Biopharma achieved revenue of $46.9M and an EBITDA of -$38.6M.
Lepu Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lepu Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $54.7M | XXX | $46.9M | XXX | XXX | XXX |
| Gross Profit | $54.7M | XXX | $37.4M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$38.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -82% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$47.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -102% | XXX | XXX | XXX |
| Net Profit | -$61.1M | XXX | -$52.5M | XXX | XXX | XXX |
| Net Margin | -112% | XXX | -112% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $50.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lepu Biopharma's stock price is HKD 5 (or $1).
Lepu Biopharma has current market cap of HKD 7.9B (or $1.0B), and EV of HKD 8.4B (or $1.1B).
See Lepu Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.0B | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lepu Biopharma has market cap of $1.0B and EV of $1.1B.
Lepu Biopharma's trades at 22.7x EV/Revenue multiple, and -27.6x EV/EBITDA.
Equity research analysts estimate Lepu Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lepu Biopharma has a P/E ratio of -18.0x.
See valuation multiples for Lepu Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 21.2x | XXX | 22.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -27.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -22.3x | XXX | XXX | XXX |
| EV/Gross Profit | 21.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -18.0x | XXX | -19.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -32.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLepu Biopharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Lepu Biopharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lepu Biopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lepu Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -82% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 119% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 182% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lepu Biopharma acquired XXX companies to date.
Last acquisition by Lepu Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Lepu Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lepu Biopharma founded? | Lepu Biopharma was founded in 2018. |
| Where is Lepu Biopharma headquartered? | Lepu Biopharma is headquartered in Hong Kong. |
| How many employees does Lepu Biopharma have? | As of today, Lepu Biopharma has 498 employees. |
| Who is the CEO of Lepu Biopharma? | Lepu Biopharma's CEO is Dr. Ziye Sui. |
| Is Lepu Biopharma publicy listed? | Yes, Lepu Biopharma is a public company listed on HKG. |
| What is the stock symbol of Lepu Biopharma? | Lepu Biopharma trades under 02157 ticker. |
| When did Lepu Biopharma go public? | Lepu Biopharma went public in 2022. |
| Who are competitors of Lepu Biopharma? | Similar companies to Lepu Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lepu Biopharma? | Lepu Biopharma's current market cap is $1.0B |
| What is the current revenue of Lepu Biopharma? | Lepu Biopharma's last 12 months revenue is $54.7M. |
| What is the current EV/Revenue multiple of Lepu Biopharma? | Current revenue multiple of Lepu Biopharma is 21.2x. |
| Is Lepu Biopharma profitable? | Yes, Lepu Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
